Ibandronate in profile: drug characteristics and clinical efficacy.

Aged; Bone Density Conservation Agents/adverse effects/pharmacokinetics/pharmacology/therapeutic use; Diphosphonates/adverse effects/pharmacokinetics/pharmacology/therapeutic use; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal/prevention & control

Abstract :

[en] BACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitrogen-containing bisphosphonates are now one of the treatments of choice. OBJECTIVE: To review the profile of ibandronate, a monthly oral (150 mg) or quarterly intravenous injection (3 mg) of bisphosphonate. METHODS: The literature search was limited to publications of ibandronate data. RESULTS/CONCLUSION: Ibandronate is rapidly absorbed and distributed in the bone; it is not metabolised and is excreted in urine. Clinical trial data have demonstrated the efficacy of ibandronate in reducing fracture risk, increasing bone mineral density and reducing bone turnover. These data are supported by recent meta-analyses and a large database study that have demonstrated antifracture efficacy with the ibandronate regimens used in clinical practice. Overall, ibandronate has generally been well tolerated. Therefore, ibandronate is a useful treatment for postmenopausal osteoporosis.

Disciplines :

General & internal medicine

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

NEUPREZ, Audrey ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique

Language :

English

Title :

Ibandronate in profile: drug characteristics and clinical efficacy.

Publication date :

2008

Journal title :

Expert Opinion on Drug Metabolism and Toxicology

ISSN :

1742-5255

eISSN :

1744-7607

Publisher :

Informa Healthcare, United Kingdom

Volume :

Issue :

Pages :

941-51

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 August 2009

Statistics

Number of views

86 (6 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Kalpakcioglu BB, Morshed S, Engelke K, Genant HK. Advanced imaging of bone macrostructure and microstructure in bone fragility and fracture repair. J Bone Joint Surg Am 2008;90(Suppl 1):68-78
Boutroy S, Bouxsein MI, Munoz F, Delmas PD. Non invasive measurement of trabecular architecture by 3D-pQCT discriminates osteopenic women with and without fractures [abstract SA360]. J Bone Miner Res 2005;20(Suppl 1):S91
Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:S12-7
Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10
Gullberg B, Johnell O, Kanis Ja. World-wide projections far hip fracture. Osteoporos Int 1997;7:407-13
Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005 - 2025. J Bone Miner Res 2007;22:465-75
Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16:229-38
Bonviva 150mg film-coated tablets. Summary of Product Characteristics 2006
Bonviva 3mg/3ml solution far injection in pre-filled syringe. Summary of Product Characteristics 2006
Bondronat concentrate for solution for incusion. Summary of Product Characteristics 2007
Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11
Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Rep Ther 2001;296:235-42
Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. In: Heersche JNM, Kanis JA, editors, Bisphosphonates: structure-activity relationships and therapeutic implications, in bone and mineral research. Elsevier Publishing Co.: Amsterdam; 1994. p. 265-306
Ebetino FH, Dansereau SM. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, editors, Bisphosphonate antiresorptive structureactivity relationships, in bisphosphonate on bones. Elsevier Publishing Co.: Amsterdam; 1995. p. 139-53
Luckman SP, Coxon FP, Ebetino FH, et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78
Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65
Ravn P, Clemmesen B, Riis Bj, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose finding study. Bone 1996;19:527-33
Reginster J-Y, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. J Clin Endocrinol Metab 2005;90:5018-24
Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307
Christiansen C, Tankó LB, Warming L, et al. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int 2003;14:609-13
Reginster J-Y, Gieschke R. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Curr Drug Metab 2006;7:827-36
Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
Stakkestad JA, Ronald Emkey, Colin Neate, Charles H Chesnut. Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: results from a sub-analysis of a pivotal study [Abstract 152]. Bone 2008;42(Suppl. 1):S86
Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the Monthly Oral IBandronate in LadiEs (MOBILE) study. J Bone Miner Res 2005;20:1315-22
Reginster J-Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61
Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheum 2008 in press
Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-13
Collette J, Reginster J-Y, Zerbini CAF, et al. Reduction in bone remodelling markers with monthly oral ibandronate (150mg) and weekly alendronate (70mg): results from the MOTION study [abstract P474]. Osteoporos Int 2008;19(Suppl 1):S207
Recker R, Stakkestad JA, Chesnut CH 3rd, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890-9
Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA study. Arthritis Rheum 2006;54:1838-46
Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheum 2008;35:488-97
Lewiecki EM, Pfeilschifter J, Rachela Grant, et al. Continuing improvements in the efficacy of quarterly intravenous ibandronate injection: DIVA study long-term extension [abstract 307Th]. Bone 2007;40(Suppl 2):S301
Cranney A, George Wells, Jonathan Adachi. Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data [abstract LB0004]. Ann Rheum Dis 2007;66(Suppl 2):681
Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-45
Epstein S, Delmas PD, Emkey R, et al. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas 2006;54:1-10
Brown JP, Burckhardt P, Reid IR, et al. Zoledronic acid, at a total annual dose of 4 mg, increases bone density at all sites and stably reduces bone turnover for one year when administered as a single or a 3-monthly intravenous injection in postmenopausal osteoporosis [abstract P353]. J Bone Miner Res 2001;16(Suppl 1):S218
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44
Kraj M, Pog ódR, Maj S, et al. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Pol Pharm 2002;59:478-82
Berenson JR. Zoledronic acid in cancer patients with bone metastases: results of phase I and II trials. Semin Oncol 2001;28(Suppl 6):25-34
Miller PD, Ward P, Pfister T, et al. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clin Exp Rheum 2008; in press
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72
Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006;119(Suppl 1):S12-7
Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119(Suppl 1):S18-24
Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
Cooper A, Drake J, Brankin E. The PERSIST investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905
Silverman S, Joyce A Cramer, John Sunyecz, et al. Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases [abstract W366]. J Bone Miner Res 2007;22(Suppl 1):S454
Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007;23:2193-203
Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91
Piziak VK, Babbitt AM, Kohles J, Lewiecki M. Comparable adherence and improvement in GI tolerability with monthly oral and quarterly IV ibandronate in patients who discontinued previous bisphosphonates because of GI intolerance [abstract W362]. J Bone Miner Res 2007;22(Suppl 1):S453
Garcia-Hernández PA, Carranza-Lisa S, de la Peña-Rodríguez P, et al. The impact of bonemarker feedback on adherence to once monthly ibandronate treatment for post-menopausal osteoporosis (PMO) in Mexican and Chilean patients (BOHEMIA Study) [abstract T391]. J Bone Miner Res 2007;22(Suppl 1):S330
Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis. Curr Med Res Opin 2005;21:1895-903
Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomised, crossover study (BALTO II). Joint Bone Spine 2008;75:303-10
Reginster J-Y, Blumentals WA, Barr CE, et al. Fracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study [Abstract OC17]. Osteoporos Int 2008;19(Suppl. 1):S9
Hochberg MC, Hochberg MC, Greenspan S, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92